Identification of the benzyloxyphenyl pharmacophore: A structural unit that promotes sodium channel slow inactivation

Amber M. King, Xiao Fang Yang, Yuying Wang, Erik T. Dustrude, Cindy Barbosa, Michael R. Due, Andrew D. Piekarz, Sarah M. Wilson, Fletcher A. White, Christophe Salomé, Theodore R. Cummins, Rajesh Khanna, Harold Kohn

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Four compounds that contained the N-benzyl 2-amino-3-methoxypropionamide unit were evaluated for their ability to modulate Na+ currents in catecholamine A differentiated CAD neuronal cells. The compounds differed by the absence or presence of either a terminal N-acetyl group or a (3-fluoro)benzyloxy moiety positioned at the 4′-benzylamide site. Analysis of whole-cell patch-clamp electrophysiology data showed that the incorporation of the (3-fluoro)benzyloxy unit, to give the (3-fluoro)benzyloxyphenyl pharmacophore, dramatically enhanced the magnitude of Na+ channel slow inactivation. In addition, N-acetylation markedly increased the stereoselectivity for Na+ channel slow inactivation. Furthermore, we observed that Na+ channel frequency (use)-dependent block was maintained upon inclusion of this pharmacophore. Confirmation of the importance of the (3-fluoro)benzyloxyphenyl pharmacophore was shown by examining compounds where the N-benzyl 2-amino-3-methoxypropionamide unit was replaced by a N-benzyl 2-amino-3-methylpropionamide moiety, as well as examining a series of compounds that did not contain an amino acid group but retained the pharmacophore unit. Collectively, the data indicated that the (3-fluoro)benzyloxyphenyl unit is a novel pharmacophore for the modulation of Na+ currents.

Original languageEnglish (US)
Pages (from-to)1037-1049
Number of pages13
JournalACS Chemical Neuroscience
Volume3
Issue number12
DOIs
StatePublished - Dec 19 2012
Externally publishedYes

Fingerprint

Electrophysiology
Stereoselectivity
Acetylation
Sodium Channels
Clamping devices
Catecholamines
Benzyl Compounds
Computer aided design
Modulation
Amino Acids

Keywords

  • anticonvulsant activity
  • Benzyloxyphenyl pharmacophore
  • epilepsy
  • hyperexcitable neurons
  • slow inactivation
  • voltage-gated sodium channels

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Physiology
  • Cognitive Neuroscience

Cite this

King, A. M., Yang, X. F., Wang, Y., Dustrude, E. T., Barbosa, C., Due, M. R., ... Kohn, H. (2012). Identification of the benzyloxyphenyl pharmacophore: A structural unit that promotes sodium channel slow inactivation. ACS Chemical Neuroscience, 3(12), 1037-1049. https://doi.org/10.1021/cn300129d

Identification of the benzyloxyphenyl pharmacophore : A structural unit that promotes sodium channel slow inactivation. / King, Amber M.; Yang, Xiao Fang; Wang, Yuying; Dustrude, Erik T.; Barbosa, Cindy; Due, Michael R.; Piekarz, Andrew D.; Wilson, Sarah M.; White, Fletcher A.; Salomé, Christophe; Cummins, Theodore R.; Khanna, Rajesh; Kohn, Harold.

In: ACS Chemical Neuroscience, Vol. 3, No. 12, 19.12.2012, p. 1037-1049.

Research output: Contribution to journalArticle

King, AM, Yang, XF, Wang, Y, Dustrude, ET, Barbosa, C, Due, MR, Piekarz, AD, Wilson, SM, White, FA, Salomé, C, Cummins, TR, Khanna, R & Kohn, H 2012, 'Identification of the benzyloxyphenyl pharmacophore: A structural unit that promotes sodium channel slow inactivation', ACS Chemical Neuroscience, vol. 3, no. 12, pp. 1037-1049. https://doi.org/10.1021/cn300129d
King, Amber M. ; Yang, Xiao Fang ; Wang, Yuying ; Dustrude, Erik T. ; Barbosa, Cindy ; Due, Michael R. ; Piekarz, Andrew D. ; Wilson, Sarah M. ; White, Fletcher A. ; Salomé, Christophe ; Cummins, Theodore R. ; Khanna, Rajesh ; Kohn, Harold. / Identification of the benzyloxyphenyl pharmacophore : A structural unit that promotes sodium channel slow inactivation. In: ACS Chemical Neuroscience. 2012 ; Vol. 3, No. 12. pp. 1037-1049.
@article{47a57c6781734ba98d94dac670f5aa9f,
title = "Identification of the benzyloxyphenyl pharmacophore: A structural unit that promotes sodium channel slow inactivation",
abstract = "Four compounds that contained the N-benzyl 2-amino-3-methoxypropionamide unit were evaluated for their ability to modulate Na+ currents in catecholamine A differentiated CAD neuronal cells. The compounds differed by the absence or presence of either a terminal N-acetyl group or a (3-fluoro)benzyloxy moiety positioned at the 4′-benzylamide site. Analysis of whole-cell patch-clamp electrophysiology data showed that the incorporation of the (3-fluoro)benzyloxy unit, to give the (3-fluoro)benzyloxyphenyl pharmacophore, dramatically enhanced the magnitude of Na+ channel slow inactivation. In addition, N-acetylation markedly increased the stereoselectivity for Na+ channel slow inactivation. Furthermore, we observed that Na+ channel frequency (use)-dependent block was maintained upon inclusion of this pharmacophore. Confirmation of the importance of the (3-fluoro)benzyloxyphenyl pharmacophore was shown by examining compounds where the N-benzyl 2-amino-3-methoxypropionamide unit was replaced by a N-benzyl 2-amino-3-methylpropionamide moiety, as well as examining a series of compounds that did not contain an amino acid group but retained the pharmacophore unit. Collectively, the data indicated that the (3-fluoro)benzyloxyphenyl unit is a novel pharmacophore for the modulation of Na+ currents.",
keywords = "anticonvulsant activity, Benzyloxyphenyl pharmacophore, epilepsy, hyperexcitable neurons, slow inactivation, voltage-gated sodium channels",
author = "King, {Amber M.} and Yang, {Xiao Fang} and Yuying Wang and Dustrude, {Erik T.} and Cindy Barbosa and Due, {Michael R.} and Piekarz, {Andrew D.} and Wilson, {Sarah M.} and White, {Fletcher A.} and Christophe Salom{\'e} and Cummins, {Theodore R.} and Rajesh Khanna and Harold Kohn",
year = "2012",
month = "12",
day = "19",
doi = "10.1021/cn300129d",
language = "English (US)",
volume = "3",
pages = "1037--1049",
journal = "ACS Chemical Neuroscience",
issn = "1948-7193",
publisher = "American Chemical Society",
number = "12",

}

TY - JOUR

T1 - Identification of the benzyloxyphenyl pharmacophore

T2 - A structural unit that promotes sodium channel slow inactivation

AU - King, Amber M.

AU - Yang, Xiao Fang

AU - Wang, Yuying

AU - Dustrude, Erik T.

AU - Barbosa, Cindy

AU - Due, Michael R.

AU - Piekarz, Andrew D.

AU - Wilson, Sarah M.

AU - White, Fletcher A.

AU - Salomé, Christophe

AU - Cummins, Theodore R.

AU - Khanna, Rajesh

AU - Kohn, Harold

PY - 2012/12/19

Y1 - 2012/12/19

N2 - Four compounds that contained the N-benzyl 2-amino-3-methoxypropionamide unit were evaluated for their ability to modulate Na+ currents in catecholamine A differentiated CAD neuronal cells. The compounds differed by the absence or presence of either a terminal N-acetyl group or a (3-fluoro)benzyloxy moiety positioned at the 4′-benzylamide site. Analysis of whole-cell patch-clamp electrophysiology data showed that the incorporation of the (3-fluoro)benzyloxy unit, to give the (3-fluoro)benzyloxyphenyl pharmacophore, dramatically enhanced the magnitude of Na+ channel slow inactivation. In addition, N-acetylation markedly increased the stereoselectivity for Na+ channel slow inactivation. Furthermore, we observed that Na+ channel frequency (use)-dependent block was maintained upon inclusion of this pharmacophore. Confirmation of the importance of the (3-fluoro)benzyloxyphenyl pharmacophore was shown by examining compounds where the N-benzyl 2-amino-3-methoxypropionamide unit was replaced by a N-benzyl 2-amino-3-methylpropionamide moiety, as well as examining a series of compounds that did not contain an amino acid group but retained the pharmacophore unit. Collectively, the data indicated that the (3-fluoro)benzyloxyphenyl unit is a novel pharmacophore for the modulation of Na+ currents.

AB - Four compounds that contained the N-benzyl 2-amino-3-methoxypropionamide unit were evaluated for their ability to modulate Na+ currents in catecholamine A differentiated CAD neuronal cells. The compounds differed by the absence or presence of either a terminal N-acetyl group or a (3-fluoro)benzyloxy moiety positioned at the 4′-benzylamide site. Analysis of whole-cell patch-clamp electrophysiology data showed that the incorporation of the (3-fluoro)benzyloxy unit, to give the (3-fluoro)benzyloxyphenyl pharmacophore, dramatically enhanced the magnitude of Na+ channel slow inactivation. In addition, N-acetylation markedly increased the stereoselectivity for Na+ channel slow inactivation. Furthermore, we observed that Na+ channel frequency (use)-dependent block was maintained upon inclusion of this pharmacophore. Confirmation of the importance of the (3-fluoro)benzyloxyphenyl pharmacophore was shown by examining compounds where the N-benzyl 2-amino-3-methoxypropionamide unit was replaced by a N-benzyl 2-amino-3-methylpropionamide moiety, as well as examining a series of compounds that did not contain an amino acid group but retained the pharmacophore unit. Collectively, the data indicated that the (3-fluoro)benzyloxyphenyl unit is a novel pharmacophore for the modulation of Na+ currents.

KW - anticonvulsant activity

KW - Benzyloxyphenyl pharmacophore

KW - epilepsy

KW - hyperexcitable neurons

KW - slow inactivation

KW - voltage-gated sodium channels

UR - http://www.scopus.com/inward/record.url?scp=84871318530&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871318530&partnerID=8YFLogxK

U2 - 10.1021/cn300129d

DO - 10.1021/cn300129d

M3 - Article

C2 - 23259039

AN - SCOPUS:84871318530

VL - 3

SP - 1037

EP - 1049

JO - ACS Chemical Neuroscience

JF - ACS Chemical Neuroscience

SN - 1948-7193

IS - 12

ER -